The world may have a dengue vaccine soon as Sanofi Pasteur has received approval from the Mexican government to market the first ever dengue vaccine that can prevent the fastest growing mosquito-borne disease in the world today.

In a press release, Swiftwater vaccine maker Sanofi informed that its tetravalent dengue vaccine Dengvaxia is capable of helping patients with the mosquito-borne disease caused by all four dengue virus types. “In two studies, the vaccine reduced dengue from all four viral variations in two-thirds of the participants. It also showed that the vaccine prevented 9 out of 10 cases of severe dengue and 8 out 10 hospitalizations due to dengue in this age group”, as per the company.

Dr. Olivier Brandicourt, Chief Executive Officer of Sanofi, said in a statement that getting green signal from the Mexican government is a historic milestone for the Paris headquartered company and for the global public health community. Dengvaxia can be a life-savior for 50% of the world’s current population which is living with the risk of developing dengue, Olivier added.

The company also said that it has started taking steps to make the vaccine. Manufacturing of a new facility on Swiftwater campus has started earlier. Adding to that, Sanofi has also started building a new quality control facility to support researches. According to the company’s plans, the first doses of Dengvaxia have been produced. The production will be reaching 100 million vaccine doses annually, the company revealed.